Novo: semaglutide superior to Januvia

Novo Nordisk A/S (CSE:NVO; NYSE:NVO) said once-weekly 0.5 mg and 1.0 mg doses of subcutaneous semaglutide ( NN9535) were superior to once-daily Januvia sitagliptin from Merck & Co. Inc. (NYSE:MRK) in reducing baseline HbA1c and body weight in the Phase IIIa SUSTAIN 2 trial to treat Type II diabetes.

In the 1,231-patient, 56-week trial, 0.5 mg and 1.0 mg semaglutide reduced HbA1c from baseline by 1.3% and 1.6%, respectively, compared to 0.5% for 100 mg Januvia, achieving the study's primary endpoint. ...